Ligand id: 9047

Name: eldelumab

No information available.
Summary of Clinical Use
Eldelumab has been evaluated in Phase II clinical trials for rheumatoid arthritis [3] and ulcerative colitis (NCT00656890) [2]. The antibody showed efficacy in both conditions.
Mechanism Of Action and Pharmacodynamic Effects
Eldelumab potently binds CXCL10 and prevents it from binding to its receptor CXCR3. CXCR3 is expressed only on activated T cells. Antibody-induced blockade of CXCR3 activation is expected to produce an anti-inflammatory effect.